Nanobiotix Company Description

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.

Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.

Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Nanobiotix S.A.

Country	France
Founded	2003
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	103
CEO	Laurent Levy

Contact Details

Address: 60 rue de Wattignies Paris, 75012 France
Phone	33 1 40 26 04 70
Website	nanobiotix.com

Stock Details

Ticker Symbol	0QAV
Exchange	London Stock Exchange
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR0011341205
SIC Code	2836

Key Executives

Name	Position
Laurent Levy Ph.D.	Co-Founder, President of the Executive Board and Chief Executive Officer
Bart Van Rhijn	Chief Financial and Business Officer and Member of Executive Board
Anne-Juliette Hermant M.A.	Chief People Officer and Member of Executive Board
Dr. Louis Kayitalire M.D.	Chief Medical Officer and Member of Executive Board
Earl J. Bergey Ph.d.	Co-Founder
Brandon Owens	Vice President of Strategic Marketing and Corporate Communication
Margaret Galluzzi	Vice President and Global Head of Clinical Operations
Dr. Leonard A. Farber M.D.	Chief Clinical and Medical Affairs Officer and Chairman of the Scientific Advisory Board